Leg swelling after inguinal sentinel lymph node biopsy and primary melanoma excision with a safety margin

2012 ◽  
Vol 10 (10) ◽  
pp. 733-738
Author(s):  
Lutz Kretschmer ◽  
Aila Luise Pratsch
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Safety Margin ◽  
Primary Melanoma ◽  
Lymph Node Biopsy ◽  
Node Biopsy

scholarly journals Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma

Cancer ◽  
2006 ◽  
Vol 107 (11) ◽  
pp. 2647-2652 ◽  
Author(s):  
Christopher J. Gannon ◽  
Dennis L. Rousseau ◽  
Merrick I. Ross ◽  
Marcella M. Johnson ◽  
Jeffrey E. Lee ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Local Excision ◽  
Wide Local Excision ◽  
Lymphatic Mapping ◽  
Primary Melanoma ◽  
Lymph Node Biopsy ◽  
Node Biopsy

Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma

2013 ◽  
pp. e320-e325
Author(s):  
Vernon K. Sondak ◽  
Sandra L. Wong ◽  
Jeffrey E. Gershenwald ◽  
John F. Thompson
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Sentinel Node ◽  
Primary Melanoma ◽  
Lymph Node Biopsy ◽  
Evidence Based ◽  
Node Negative ◽  
Nodal Basin ◽  
Node Biopsy

Sentinel lymph node biopsy (SLNB) was introduced in 1992 to allow histopathologic evaluation of the “sentinel” node, that is, the first node along the lymphatic drainage pathway from the primary melanoma. This procedure has less risk of complications than a complete lymphadenectomy, and if the sentinel node is uninvolved by tumor the likelihood a complete lymphadenectomy would find metastatic disease in that nodal basin is very low. SLNB is now widely used worldwide in the staging of melanoma as well as breast and Merkel cell carcinomas. SLNB provides safe, reliable staging for patients with clinically node-negative melanomas 1 mm or greater in thickness, with an acceptably low rate of failure in the sentinel node-negative basin. Evidence-based guidelines jointly produced by ASCO and the Society of Surgical Oncology (SSO) recommend SLNB for patients with intermediate-thickness melanomas and also state that SLNB may be recommended for patients with thick melanomas. Major remaining areas of uncertainty include the indications for SLNB in patients with thin melanomas, pediatric patients, and patients with atypical melanocytic neoplasms; the optimal radiotracers and dyes for lymphatic mapping; and the necessity of complete lymphadenectomy in all sentinel node-positive patients.

scholarly journals Sentinel Lymph Node Biopsy in Head and Neck Cutaneous Malignant Melanoma

2019 ◽  
Vol 77 (2) ◽  
pp. 129-133
Author(s):  
Ana Marta António ◽  
Cecília Moura ◽  
Carina Semedo ◽  
Sandra Bitoque ◽  
Mariluz Martins ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Head And Neck ◽  
Cutaneous Melanoma ◽  
Primary Melanoma ◽  
Lymph Node Biopsy ◽  
Superficial Spreading ◽  
Node Biopsy ◽  
Head And Neck Melanoma

Introduction: Sentinel lymph node biopsy (SLNB) is the standard of care for cutaneous melanoma, including head and neck melanoma. The aim of this study was to analyze and characterize SLNB in a population of head and neck melanoma patients. Methods: A unicentric, retrospective study on patients with cutaneous head and neck melanoma who underwent SLNB in the Department of Head and Neck Surgery at the Portuguese Institute of Oncology (IPO) Lisbon between January 2010 and December 2017 was performed. The location of primary melanoma, the identification of SLN, the number of the excised SLN, its lymphatic basin origin and the presence of infraclinic metastasis were analysed. Results:  Ninety-eight patients were eligible to undergo SLNB during the observation period. The most frequent locations of primary melanoma were the scalp (24.5%) and the auricular and periauricular region (23.5%) and the most frequent variants were the superficial spreading melanoma (40.8%) and nodular melanoma (30.6%). SLNB was successfully executed in 78 patients (79.6%). A mean of 3.8 lymph-nodes per patient were excised and in 16.7% SLN were excised in more than one lymphatic basin. The SLN were identified in parotid region (39.8%), level II (29.5%) and level V (18.2%). SLN metastases were detected in 13 patients (16.7%). Conclusion: Surgical approach of head and neck cutaneous melanoma is particularly complex. The redundancy of lymphatic system, the multiple SLN and SLN basins influence the SLNB success and may contribute to high rates of false-negatives with its prognostic implications. All patients should be carefully monitored.  

Wide local excision prior to sentinel lymph node biopsy for primary melanoma of the head and neck

2019 ◽  
Vol 58 (10) ◽  
pp. 1184-1190 ◽  
Author(s):  
Matthew M. May ◽  
Christine M. Lohse ◽  
Eric J. Moore ◽  
Daniel L. Price ◽  
Kathryn M. Van Abel ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Head And Neck ◽  
Local Excision ◽  
Wide Local Excision ◽  
Primary Melanoma ◽  
Lymph Node Biopsy ◽  
Node Biopsy

Role for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Thick (?4 mm) Primary Melanoma

2000 ◽  
Vol 7 (2) ◽  
pp. 160-165 ◽  
Author(s):  
Jeffrey E. Gershenwald ◽  
Paul F. Mansfield ◽  
Jeffrey E. Lee ◽  
Merrick I. Ross
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Lymphatic Mapping ◽  
Primary Melanoma ◽  
Lymph Node Biopsy ◽  
Node Biopsy

scholarly journals 1243 Sentinel Lymph Node Biopsy for Melanoma during the COVID-19 Pandemic

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
T Stubley ◽  
B El-Khayat
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Primary Melanoma ◽  
Lymph Node Biopsy ◽  
Newly Diagnosed ◽  
Hospital Site ◽  
Node Biopsy ◽  
Clinical Literature ◽  
Number Of Patients

Abstract Aim Sentinel lymph node biopsy (SLNB) is an established aspect of the staging process for primary melanoma, with the results dictating future treatment methods. Due to the COVID-19 pandemic no SLNBs were offered to patients with newly diagnosed melanoma at a hospital site in the West Midlands. The aim of this study was to identify the number of patients who missed out on this investigation in order to ascertain how many patients with a potential positive SLNB were missed. Method A patient list was provided from the dermatology and plastic surgery database, ensuring that all newly diagnosed melanoma patients throughout the period March-May 2020 were included. A retrospective study design was utilised, with all data collected from the computer system at a single hospital site. Results 64 patients were provided via the patient list, of which 44 were appropriate for SLNB using the NICE criteria. After detailed reading of the patient notes, 80% (35/44) of patients were provided with a reason why they did not receive a SLNB, however the remaining 20% (9/44) did not have this clearly recorded. Conclusions A large cohort of patients did not receive a SLNB during the COVID-19 pandemic. Utilising the clinical literature, it can be predicted that around 9 of these patients would have had a SLNB that identified metastasis. These patients have potentially missed out on adjuvant treatment, and the cohort will therefore require follow up to be adapted to reflect this.

Role of Sentinel Lymph Node Biopsy in Patients With Thin (<1 mm) Primary Melanoma

2003 ◽  
Vol 10 (5) ◽  
pp. 558-561 ◽  
Author(s):  
Ira A. Jacobs ◽  
C. K. Chang ◽  
Tapas K. DasGupta ◽  
George I. Salti
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Primary Melanoma ◽  
Lymph Node Biopsy ◽  
Node Biopsy
Sign in / Sign up

Export Citation Format

Share Document